Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
Toda Y, Iwatsubo T, Nakamura Y, Matsuda N, Miyata M, Jin M, Chen T, Kuribayashi K, Tian Y, Hughes R, Yamamoto J, Muralidharan KK, Rubel C, Hutchison RM, Budd Haeberlein S. Toda Y, et al. Among authors: miyata m. J Prev Alzheimers Dis. 2024;11(5):1260-1269. doi: 10.14283/jpad.2024.106. J Prev Alzheimers Dis. 2024. PMID: 39350371 Free PMC article. Clinical Trial.
Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T; Alzheimer’s Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Kikuchi M, et al. Alzheimers Res Ther. 2024 Feb 27;16(1):45. doi: 10.1186/s13195-024-01414-x. Alzheimers Res Ther. 2024. PMID: 38414085 Free PMC article.
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer's disease patients.
Kondo T, Hara N, Koyama S, Yada Y, Tsukita K, Nagahashi A, Ikeuchi T, Ishii K, Asada T, Arai T, Yamada R; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI); Inoue H. Kondo T, et al. Nat Aging. 2022 Feb;2(2):125-139. doi: 10.1038/s43587-021-00158-9. Epub 2022 Feb 17. Nat Aging. 2022. PMID: 37117761
Correction: Polygenic effects on the risk of Alzheimer's disease in the Japanese population.
Kikuchi M, Miyashita A, Hara N, Kasuga K, Saito Y, Murayama S, Kakita A, Akatsu H, Ozaki K, Niida S, Kuwano R, Iwatsubo T, Nakaya A, Ikeuchi T; Alzheimer’s Disease Neuroimaging Initiative; Japanese Alzheimer’s Disease Neuroimaging Initiative. Kikuchi M, et al. Alzheimers Res Ther. 2024 Jul 10;16(1):158. doi: 10.1186/s13195-024-01514-8. Alzheimers Res Ther. 2024. PMID: 38987831 Free PMC article. No abstract available.
Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid.
Kasuga K, Kikuchi M, Tsukie T, Suzuki K, Ihara R, Iwata A, Hara N, Miyashita A, Kuwano R, Iwatsubo T, Ikeuchi T; Japanese Alzheimer’s Disease Neuroimaging Initiative. Kasuga K, et al. BMJ Neurol Open. 2022 Aug 10;4(2):e000321. doi: 10.1136/bmjno-2022-000321. eCollection 2022. BMJ Neurol Open. 2022. PMID: 36046332 Free PMC article.
Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
Matsuzaki M, Ogihara T, Umemoto S, Rakugi H, Matsuoka H, Shimada K, Abe K, Suzuki N, Eto T, Higaki J, Ito S, Kamiya A, Kikuchi K, Suzuki H, Tei C, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Matsuzaki M, et al. J Hypertens. 2011 Aug;29(8):1649-59. doi: 10.1097/HJH.0b013e328348345d. J Hypertens. 2011. PMID: 21610513 Clinical Trial.
Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events COPE Trial Group. Umemoto S, et al. Hypertens Res. 2016 Jan;39(1):46-53. doi: 10.1038/hr.2015.104. Epub 2015 Oct 22. Hypertens Res. 2016. PMID: 26490089 Free PMC article. Clinical Trial.
Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.
Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group. Umemoto S, et al. Hypertens Res. 2017 Apr;40(4):376-384. doi: 10.1038/hr.2016.158. Epub 2016 Dec 1. Hypertens Res. 2017. PMID: 27904156 Free PMC article. Clinical Trial.
Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial.
Rakugi H, Ogihara T, Umemoto S, Matsuzaki M, Matsuoka H, Shimada K, Higaki J, Ito S, Kamiya A, Suzuki H, Ohashi Y, Shimamoto K, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events Trial Group. Rakugi H, et al. Hypertens Res. 2013 Nov;36(11):947-58. doi: 10.1038/hr.2013.63. Epub 2013 Jul 18. Hypertens Res. 2013. PMID: 23864054 Clinical Trial.
1,669 results